EBITDA Margin % is calculated as EBITDA divided by its Revenue. PaxMedica's EBITDA for the
three
months ended in Jun. 2024 was $-3.00 Mil. PaxMedica's Revenue for the
three
months ended in Jun. 2024 was $0.00 Mil. Therefore, PaxMedica's EBITDA margin for the quarter that ended in Jun. 2024 was 0.00%.
PaxMedica EBITDA Margin % Historical Data
The historical data trend for PaxMedica's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PaxMedica's EBITDA Margin %
For the Biotechnology subindustry, PaxMedica's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PaxMedica's EBITDA Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PaxMedica's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PaxMedica's EBITDA Margin % falls into.
PaxMedica EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
PaxMedica's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PaxMedica EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of PaxMedica's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PXMD has been successfully added to your 